Mikolaj Milewski, Ph.D. - Publications

Affiliations: 
2011 University of Kentucky, Lexington, KY 

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Ghosh P, Milewski M, Paudel K. In vitro/in vivo correlations in transdermal product development. Therapeutic Delivery. PMID 26419538 DOI: 10.4155/tde.15.72  0.84
2014 Eldridge JA, Milewski M, Stinchcomb AL, Crooks PA. Synthesis and in vitro stability of amino acid prodrugs of 6-β-naltrexol for microneedle-enhanced transdermal delivery. Bioorganic & Medicinal Chemistry Letters. 24: 5212-5. PMID 25442314 DOI: 10.1016/J.Bmcl.2014.09.072  0.84
2013 Milewski M, Paudel KS, Brogden NK, Ghosh P, Banks SL, Hammell DC, Stinchcomb AL. Microneedle-assisted percutaneous delivery of naltrexone hydrochloride in yucatan minipig: in vitro-in vivo correlation. Molecular Pharmaceutics. 10: 3745-57. PMID 24053426 DOI: 10.1021/Mp400227E  0.84
2012 Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release : Official Journal of the Controlled Release Society. 163: 220-9. PMID 22929967 DOI: 10.1016/J.Jconrel.2012.08.015  0.84
2012 Milewski M, Stinchcomb AL. Estimation of maximum transdermal flux of nonionized xenobiotics from basic physicochemical determinants. Molecular Pharmaceutics. 9: 2111-20. PMID 22702370 DOI: 10.1021/Mp300146M  0.84
2012 Milewski M, Pinninti RR, Stinchcomb AL. Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin. Journal of Pharmaceutical Sciences. 101: 2777-86. PMID 22628183 DOI: 10.1002/Jps.23189  0.84
2011 Milewski M, Stinchcomb AL. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharmaceutical Research. 28: 124-34. PMID 20577787 DOI: 10.1007/S11095-010-0191-X  0.84
2010 Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic Delivery. 1: 109-31. PMID 21132122 DOI: 10.4155/Tde.10.16  0.84
2010 Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. In vitro permeation of a pegylated naltrexone prodrug across microneedle-treated skin. Journal of Controlled Release : Official Journal of the Controlled Release Society. 146: 37-44. PMID 20678989 DOI: 10.1016/J.Jconrel.2010.05.034  0.84
2010 Yerramreddy TR, Milewski M, Penthala NR, Stinchcomb AL, Crooks PA. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery. Bioorganic & Medicinal Chemistry Letters. 20: 3280-3. PMID 20451376 DOI: 10.1016/J.Bmcl.2010.04.049  0.84
2010 Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion On Drug Delivery. 7: 617-29. PMID 20205604 DOI: 10.1517/17425241003663228  0.84
Show low-probability matches.